# Digitization to take the Allergic Rhinitis Market to the exponential curve
Author:  Pal Sinha, Barnali 
Author URL: https://financedigest.com/author/pal-sinha-barnali
Published: 2021-11-29
Category: Research Reports
Category URL: https://financedigest.com/category/research-reports
Meta Title: Re-Inventing The Methodical Wheel In The Allergic Rhinitis Market
Meta Description: Discover the latest trends, growth projections, and key players shaping the global allergic rhinitis treatment market. Get a custom scope tailored to your
URL: https://financedigest.com/digitization-to-take-the-allergic-rhinitis-market-to-the-exponential-curvehtml

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qst7v3003gwirgwqtxn8i8/images/research-report-2-1736836835676-compressed.jpg)

The Allergic Rhinitis Market is likely to mark stellar growth in the upcoming period. The current situation calls for conducive integrated healthcare models that do away with middlemen regarding offering various products and services. Drug manufacturers, hospital systems, PBMs (pharmacy benefit managers), wholesale distributors, hospital systems, medical [insurers](https://www.financedigest.com/different-countries-different-insurance-cultures-how-insurers-can-adapt-their-products.html "insurers"), and retail pharmacy outlets – are all into the integration of healthcare strategies. This would be how the healthcare vertical function in the upcoming period.

The [**Allergic Rhinitis Market**](https://www.persistencemarketresearch.com/market-research/allergic-rhinitis-market.asp) is bound to reach **US$ 7,000 Million** at a **CAGR of 7.5%** between 2024. The modern-day situation says that the healthcare sector is witnessing an optimization and reposition of the business [models to obtain enhanced](https://www.financedigest.com/aon-empowers-cat-modellers-to-run-any-model-on-its-enhanced-elements-10-platform.html "AON EMPOWERS CAT MODELLERS TO RUN ANY MODEL ON ITS ENHANCED ELEMENTS 10 PLATFORM") patient outcomes. With real-time [analytics known to improve](https://www.financedigest.com/how-to-use-momentum-analytics-software-to-improve-portfolio-performance.html "How to use momentum analytics software to improve portfolio performance") patient care and the fact that consumers are shifting towards the preventive model of care, the healthcare vertical is likely to witness greater strides in the forecast period.

“Technological advancements in the medical [world](https://www.financedigest.com/shakedown-on-horizon-for-financial-technology-world.html "Shakedown on horizon for financial technology world") and rising prevalence of foodborne diseases will primarily build the market for allergic rhinitis treatment globally. Secondarily, strategic partnerships and synergies between big brands, soaring usage of second-generation multiplex immunoassay, and [augmenting R&D activities in life sciences and molecular diagnostics will support the market](https://www.financedigest.com/innovation-to-augment-the-immunoassay-interference-blocker-market.html "Innovation to augment the Immunoassay Interference Blocker Market") surge within the next few years.

Over 2016-2020, the global AR [treatment market](https://www.financedigest.com/customized-innovation-to-drive-the-alopecia-treatment-market.html "Customized innovation to drive the Alopecia Treatment Market") will reach **US$ 14 Bn**, which will further take a leap to **US$ 16.038 Bn** by the end of 2024. Over 2016-2024, the [market is likely to see impressive growth at a healthy CAGR](https://www.financedigest.com/iv-bag-market-projected-to-exhibit-a-high-single-digit-cagr-through-2027.html "IV Bag Market Projected to Exhibit a High Single-Digit CAGR through 2027") of 7.5% _._”

**Get Going With Sample Of Allergic Rhinitis Market Report!** **https://www.persistencemarketresearch.co/samples/12154**

**Company Profiles**

- Merck & Co.
- Boehringer Ingelheim
- AstraZeneca
- GlaxoSmithKline PLC
- Sanofi S.A.
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Alcon (Novartis AG)

**Get A Customized Scope To Match Your Need Ask An Expert –** [**sales@persistencemarketresearch.com**](mailto:msales@persistencemarketresearch.com)

**How About Re-Inventing The Methodical Wheel In The Allergic Rhinitis Market? Switch Over To The “Methodology” Tab!** **https://www.persistencemarketresearch.co/methodology/12154**

**[– Market](https://www.financedigest.com/turpentine-market-anticipated-to-exceed-us-1-51-bn-by-2028-fmi.html "Turpentine Market anticipated to exceed US$ 1.51 Bn by 2028 – FMI") Research Expert, Life Sciences & Transformational Health, Persistence Market Research.**

[According to Persistence Market Research’s recent report](https://www.financedigest.com/september-tropical-cyclones-cost-global-economy-more-than-4bn-according-to-aon-catastrophe-report.html "September tropical cyclones cost global economy more than bn, according to Aon catastrophe report") titled “Global Allergic Rhinitis Treatment Market: Industry Analysis and Forecast, 2016–2024,” key market competitors have embraced different strategic moves in order to strengthen their positions in the global allergic rhinitis treatment marketplace. These activities, according to Persistence [Market Research, will boost the overall status of the market in near](https://www.financedigest.com/mull-it-over-living-near-the-uks-best-christmas-markets.html "Mull it over: Living near the UK’s best Christmas markets") future.

- Merck & Co. and Johnson & Johnson are concentrating on new product development, such as nasal sprays.
- Boehringer Ingelheim will continue to contribute a major [share to the market through an increased focus](https://www.financedigest.com/european-shares-rebound-with-focus-on-italian-politics-earnings.html "European shares rebound with focus on Italian politics, earnings") on R&D and a strong distribution network.
- Sanofi S.A. is also focusing more on increasing R&D investments directed to expanded sales.
- In addition to growing R&D efforts, AstraZeneca is also emphasizing on innovation of [technologically advanced products and acquisition of selective](https://www.financedigest.com/kelda-technology-selected-as-one-of-thetop-30-cleantech-companies-in-the-world.html "Kelda Technology selected as one of thetop 30 cleantech companies in the world") regional players.
- GlaxoSmithKline PLC and Alcon (Novartis AG) are prioritising cost-effective [product development for long-term](https://www.financedigest.com/the-psychology-of-long-term-remote-working-productivity-vs-inclusivity.html "The psychology of long-term remote working: Productivity vs. Inclusivity") profits; Alcon specifically aims to tap into emerging markets.
- Acquisition of players from the same segment and different region will be a key strategy of Teva Pharmaceutical Industries Ltd., which targets production capacity expansion.

**By disease type**, perennial AR segment will [remain dominant with around 47% market value share](https://www.financedigest.com/barclays-announces-sale-of-remaining-shares-in-south-africas-absa.html "Barclays announces sale of remaining shares in South Africa’s Absa") in 2024, gaining around 123 BPS throughout the forecast period. On the other hand, despite losing over 30 BPS over 2016-2024, occupational AR will continue to be the second largest segment with over 35% revenue [share at the end](https://www.financedigest.com/european-shares-end-five-day-losing-streak-still-down-for-the-week.html "European shares end five-day losing streak, still down for the week") of the assessment period. While the revenues of the former are expected to surpass US$ 7.0 Bn, the latter will possibly exceed a value of US$ 5.0 Bn by the end of 2024.

**Keeping A Tab On Key Players In The Allergic Rhinitis Market? Go To “Purchase Now” To Decipher The Competitive Analysis In Our Allergic Rhinitis Market Report!** [**https://www.persistencemarketresearch.com/checkout/12154**](https://www.persistencemarketresearch.com/checkout/12154)

**By treatment type**, immunotherapy [**treatment**](https://www.persistencemarketresearch.com/market-research/asthma-treatment-market.asp) segment is expected to be the fastest growing segment over the forecast owing to introduction of new immunotherapy based products, followed by antihistamines segment. However, antihistamines will [continue to be the leading](https://www.financedigest.com/adnami-welcomes-svenja-damzog-as-publisher-director-dach-to-lead-continued-expansion-in-the-region.html "Adnami welcomes Svenja Damzog as Publisher Director DACH to lead continued expansion in the region") treatment type segment with over 50% share in 2024, followed by corticosteroids with over 31% share.

**Based on** [route of administration, oral route of administration segment will cover nearly half of the market](https://www.financedigest.com/britains-market-rout-stokes-contagion-fears-around-the-globe.html "Britain’s market rout stokes contagion fears around the globe") in terms of value, whereas nasal route of administration segment is anticipated to capture around 38% share of the total market value in 2024. Intravenous segment is foreseen to witness a higher CAGR compared to others, which can uplift the [sales revenues](https://www.financedigest.com/digital-sales-transformation-is-key-to-faster-higher-revenue.html "Digital sales transformation is key to faster, higher revenue") of this segment to cross US$ 1.25 Bn in 2024.

**On the basis of distribution channel**, retail pharmacies will account for higher revenues than hospital pharmacies throughout the assessed period. Retail pharmacy revenues are likely to surpass US$ 7.0 Bn, [growing at the fastest CAGR](https://www.financedigest.com/fibre-to-the-home-market-to-grow-at-a-high-14-4-cagr.html "Fibre to the Home Market to grow at a high 14.4% CAGR") of 3.9% over 2016-2024. Whereas, hospital pharmacies will reach over US$ 5.0 Bn, accounting for around 31% share of the [market value](https://www.financedigest.com/scissor-lifts-market-to-reach-a-value-of-us-4-5-bn-by-2031.html "Scissor Lifts Market to reach a value of ~US$ 4.5 Bn by 2031.") in 2024.

 **As per the** geographical assessment of the global allergic rhinitis treatment market, North America will continue to capture the maximum revenue share over the 10-year tenure. With over 63% value share by 2024-end, this region is likely to surpass US$ 10.0 Bn in [terms of revenues](https://www.financedigest.com/chemical-injection-metering-pumps-valves-market-to-surge-at-a-robust-pace-in-terms-of-revenue-over-2021-2031.html "Chemical Injection Metering Pumps & Valves Market to Surge at a Robust Pace in Terms of Revenue over 2021 – 2031"). [European market](https://www.financedigest.com/gumgum-appoints-harmen-tjaarda-as-managing-director-for-four-european-markets.html "GumGum appoints Harmen Tjaarda as Managing Director for four European markets") will possibly attract the revenues worth US$ 3.68 Bn by 2024 end, contributing over 22% share of the market size. The third key region i.e. APAC is estimated to reach over US$ 1.27 Bn in 2024.

**About us:** [**Persistence Market Research**](https://www.persistencemarketresearch.com/about-us.asp)

**Contact us:**

**Persistence Market Research**

Address – 305 Broadway, 7th Floor, New York City,

NY 10007 United States

U.S. Ph. – +1-646-568-7751

USA-Canada Toll-free – +1 800-961-0353

**Sales** – sales@persistencemarketresearch.com


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---